ReVision Implant, a Belgian neurotech startup based in Leuven, has secured FDA Breakthrough Device Designation for its Occular visual cortical prosthesis. The designation fast-tracks the regulatory pathway for a system designed to restore functional vision by stimulating the brain directly, bypassing the eyes entirely.
The Occular system works in three stages. A wireless headset camera captures visual data, converts it into electrical stimulation patterns, and transmits those patterns to micro-electrode arrays implanted in the visual cortex. The brain interprets the stimulation as visual perception. ReVision claims the system can produce greyscale image quality equivalent to over 1,000 pixels, covering enough of the visual cortex to restore both peripheral and central vision.
Why It Matters
Most vision restoration efforts in the BCI space have focused on retinal implants or optic nerve stimulation. ReVision’s approach targets a different and potentially larger patient population: people whose blindness originates upstream of the retina, where conventional implants cannot help. By placing electrodes directly on the visual cortex, the system sidesteps damaged or absent eyes and optic nerves altogether.
The technical challenge is considerable. Implanting thousands of electrodes in cortical tissue without causing lasting damage requires precision at the cellular level. ReVision says its ultra-flexible micro-electrode arrays are each as thin as a single cell, and that a patented insertion technique minimises scar tissue formation. The company claims the device meets the FDA’s ten-year minimum lifetime standard under continuous stimulation.
What Comes Next
The Breakthrough Device Designation does not mean the Occular system is approved for sale. It means ReVision now has access to the FDA’s Total Product Life-Cycle Advisory Program, which provides early feedback on clinical protocols and regulatory strategy. The practical effect is a shorter, more predictable path to market.
ReVision plans a short-term trial during scheduled brain surgery in October 2026, followed by early-stage human clinical trials in blind volunteers beginning in summer 2027, pending regulatory clearance.
The Competitive Landscape
The designation arrives at a moment of accelerating activity in visual BCIs. Science Corp raised $230 million in its Series C earlier this month for its Prima retinal implant. Neuralink has its Blindsight trial underway. Second Sight’s Argus II, once the only FDA-approved visual prosthesis, was discontinued in 2020 after the company ran out of money, leaving over 350 implanted patients without support. ReVision occupies a different niche from all three, betting that cortical stimulation can reach patients whom retinal approaches cannot serve.
For the broader BCI industry, the FDA’s willingness to grant breakthrough status to a cortical visual implant signals continued regulatory openness to devices that interface directly with brain tissue for sensory restoration. That openness matters as much as the technology itself.